Follow-On Biologics Could Gain From “Bolar Amendment” Ruling – Attorney
Executive Summary
A Supreme Court ruling that extends "Bolar Amendment" protection to preclinical research on new drug candidates could aid the development of follow-on biologics, attorney Kathleen Madden Williams (Palmer & Dodge) said
You may also be interested in...
Non-Patent Exclusivity Period Proposed For Biologics In Face Of Follow-Ons
A period of non-patent exclusivity for biologic products is necessary to preserve incentives for innovation in the face of follow-on biologics, attorneys argue in an article in the March/April issue of Health Affairs
Non-Patent Exclusivity Period Proposed For Biologics In Face Of Follow-Ons
A period of non-patent exclusivity for biologic products is necessary to preserve incentives for innovation in the face of follow-on biologics, attorneys argue in an article in the March/April issue of Health Affairs
Follow-Ons Off? FDA Shelves Near-Term Plans For Biologics Documents
FDA's decision not to release follow-on biologics documents in the near future suggests proponents of such products may turn their focus to Congress or the courts in an effort to establish a clear regulatory framework